Secretory Phospholipases A2

A subcategory of phospholipases A2 that are secreted from cells. They are 14 kDa proteins containing multiple disulfide-bonds and access their substrate via an interfacial binding site that interacts with phospholipid membranes. In addition specific PHOSPHOLIPASE A2 RECEPTORS can bind to and internalize the enzymes.

Also Known As:

Networked: 751 relevant articles (25 outcomes, 128 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Murakami, Makoto: 32 articles (01/2022 - 03/2002)
2.	Lambeau, Gérard: 31 articles (10/2021 - 02/2003)
3.	Gelb, Michael H: 31 articles (01/2020 - 07/2003)
4.	Taketomi, Yoshitaka: 17 articles (01/2022 - 11/2008)
5.	Mallat, Ziad: 17 articles (11/2021 - 10/2005)
6.	Yamamoto, Kei: 15 articles (01/2022 - 11/2008)
7.	De Luca, Daniele: 11 articles (01/2022 - 10/2008)
8.	Fullerton, David A: 11 articles (01/2021 - 12/2009)
9.	Meng, Xianzhong: 11 articles (01/2021 - 12/2009)
10.	Weyant, Michael J: 11 articles (01/2021 - 12/2009)

Related Diseases

1.	Inflammation (Inflammations) 11/30/2003 - "In this study, we investigated the expression of several sPLA(2)s in rodent inflammation models. " 08/01/2003 - "The aim of the present study was to test the hypothesis that sPLA2 enhances the selective uptake of HDL into the adrenals in response to acute inflammation as a possible physiological role for the sPLA2-HDL interaction. " 04/07/2000 - "A series of HDL metabolic studies were performed in transgenic mice that specifically overexpress human sPLA(2) but have no evidence of local or systemic inflammation. " 01/01/2019 - "sPLA2 is among the factors that contribute to the activation of pathways involved in inflammation. " 01/01/2019 - "Roles of secreted phospholipase A2 group IIA in inflammation and host defense."
2.	Myocardial Infarction 08/18/2009 - "PX-18 is a selective sPLA(2) inhibitor effective in reducing tissue damage resulting from myocardial infarction. " 05/01/2011 - "The decrease in myocardial infarct size and content of LTB(4) and TXB(2) after cPLA(2) inhibitor administration was greater in WT mice than in sPLA(2)V(-/-) mice. " 06/01/2009 - "Inhibition of type 2A secretory phospholipase A2 reduces death of cardiomyocytes in acute myocardial infarction." 06/10/2008 - "Furthermore, administration of a sPLA(2) inhibitor reduced myocardial infarct size and suppressed the cytotoxic activity of sPLA(2)-X(+/+) neutrophils. " 06/10/2008 - "Myocardial infarct size was also significantly reduced in lethally irradiated sPLA(2)-X(+/+) mice reconstituted with sPLA(2)-X(-/-) bone marrow compared with sPLA(2)-X(+/+) bone marrow. "
3.	Pancreatitis 10/01/2004 - "This sPLA2 inhibitor could become an effective agent for the treatment of severe acute pancreatitis." 06/09/2016 - "In this work we develop a point of care test for pancreatitis measuring concentration of secretory phospholipase A2 group IB (sPLA2-IB). " 01/01/2012 - "The pancreatitis injury was evaluated by serum AMY, sPLA2, and pancreatic pathological score. " 02/15/2010 - "The sPLA2 inhibitor attenuated the severity of pancreatitis and pancreatitis-associated adrenal injury. " 12/15/2005 - "Characterization of the acute pancreatitis induced by secretory phospholipases A2 in rats."
4.	Asthma (Bronchial Asthma) 01/01/2008 - "sPLA2 activity was not significantly greater in severe (499.9 U; 95% confidence interval (CI) 439.4 to 560.4) compared with mild to moderate asthmatic subjects (464.8; 95% CI 425.3 to 504.3) or control subjects (445.7; 95% CI 392.1 to 499.4), although it was higher in patients with acute asthma (581.6; 95% CI 541.2 to 622.0; p<0.001). " 01/01/2019 - "Function of secreted phospholipase A2 group-X in asthma and allergic disease." 07/01/2013 - "Additional insights into epithelial secreted phospholipase A2 group X in asthma." 07/01/2013 - "Regulation and function of epithelial secreted phospholipase A2 group X in asthma." 06/01/2011 - "Conclusions and Clinical Relevance These data indicate that sPLA(2) -IIA and sPLA(2) -X are the major sPLA(2) s in human airways, and suggest a link between the levels of sPLA(2) -X in the airways and several features of asthma."
5.	Rheumatoid Arthritis 01/01/2013 - "Increased concentrations of secreted phospholipase A2 type IIA (sPLA2-IIA), have been found in the synovial fluid of patients with rheumatoid arthritis. " 07/01/1996 - "Secretory phospholipase A2 as an index of disease activity in rheumatoid arthritis. " 02/01/2005 - "Although group IIA secretory phospholipase A2 (sPLA2-IIA) is known to be abundantly present in the joints of patients with rheumatoid arthritis (RA), expression of other sPLA2s in this disease has remained unknown. " 01/01/1996 - "Since the cloning of the type II sPLA2 in 1989 from rheumatoid arthritis synovial fluid, a direct or indirect participation of type II sPLA2 in the production of lipid mediators has been purposed. " 11/01/2005 - "Selective inhibitors of sPLA(2)s and specific antagonists of sPLA(2) receptors might prove useful in the treatment of allergic and autoimmune diseases, such as bronchial asthma and rheumatoid arthritis."

Related Drugs and Biologics

1.	Secretory Phospholipases A2
2.	Enzymes
3.	varespladib
4.	C-Reactive Protein
5.	Peroxidase (Myeloperoxidase)
6.	1-Alkyl-2-acetylglycerophosphocholine Esterase (PAF Acetylhydrolase)
7.	Phospholipases A2 (Phospholipase A2)
8.	Eicosanoids
9.	Cytokines
10.	Lipoproteins (Lipoprotein)

Related Therapies and Procedures

1.	Therapeutics
2.	Bone Marrow Transplantation (Transplantation, Bone Marrow)
3.	Hemoperfusion
4.	Percutaneous Coronary Intervention
5.	Intravenous Administration